Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

16 trials with published results (9%)

Research Maturity

91 completed trials (52% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.5%

13 terminated out of 174 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

14%

25 trials in Phase 3/4

Results Transparency

18%

16 of 91 completed with results

Key Signals

16 with results88% success13 terminated

Data Visualizations

Phase Distribution

97Total
Not Applicable (35)
Early P 1 (2)
P 1 (9)
P 2 (26)
P 3 (20)
P 4 (5)

Trial Status

Completed91
Unknown50
Terminated13
Withdrawn11
Recruiting4
Active Not Recruiting3

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 91 completed trials

Clinical Trials (174)

Showing 20 of 20 trials
NCT04745533WithdrawnPrimary

COVID-19 Contact Study by Antigen Detection Test

NCT04510194Phase 3Completed

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

NCT05313087CompletedPrimary

COVID-19 Vaccine Response in Chronic Respiratory Conditions

NCT05886816Phase 2RecruitingPrimary

Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19

NCT04725110Phase 2Withdrawn

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

NCT04730661Not ApplicableTerminatedPrimary

Efficacy of the Sit to Stand Test in the Decision to Hospitalize a Patient Consulting the Emergency Dept for COVID 19

NCT04802408Phase 2Active Not Recruiting

SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial

NCT04537299Phase 2Terminated

COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes

NCT04761822Phase 2CompletedPrimary

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

NCT04895475Completed

Antibody Detection of Vaccine-Induced Secretory Effects

NCT04705766RecruitingPrimary

KIDney Injury in Times of COVID-19 (KIDCOV)

NCT04546776CompletedPrimary

COVID-19 Persistence in Stool

NCT04885452CompletedPrimary

Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.

NCT04865237Not ApplicableCompleted

SARS-CoV-2 Human Challenge Characterisation Study

NCT04668339Phase 2Terminated

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

NCT04590547Phase 2Completed

GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)

NCT04961541Phase 1CompletedPrimary

Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine

NCT04780334CompletedPrimary

Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept

NCT04815096Phase 2Recruiting

Imaging Immune Activation in COVID-19

NCT04421664Phase 3Terminated

Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)

Scroll to load more

Research Network

Activity Timeline